This article is more than 5 years old. Information may no longer be current.

Ophthotech completes patient recruitment in phase 3 trial of Fovista in combination with Lucentis

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Ophthotech has completed patient recruitment in the second phase 3 trial of Fovista in combination with Lucentis for the treatment of wet age-related macular degeneration, the company announced in a press release.

The two phase 3 clinical trials are investigating the superiority of Fovista (pegpleranib, Ophthotech) in combination with Lucentis (ranibizumab, Genentech) over Lucentis monotherapy. Data from the two clinical trials will be analyzed together “to optimize pooled analysis of certain relevant endpoints in accordance with the statistical analysis plan,” the release said.

“We believe that Fovista administered in combination with anti-VEGF therapy may represent a significant advancement in the treatment of wet AMD, and we look forward to obtaining data from both of these studies,” David R. Guyer, MD, CEO and chairman of the board of Ophthotech, said in the release.

The company expects to announce topline results from both phase 3 clinical trials in the fourth quarter of 2016.